Androgens in prostate cancer: A tale that never ends
Androgens in prostate cancer: A tale that never ends
复制标题
追踪前列腺活检样本中的类固醇生成，揭示前列腺组织雄激素代谢特征和潜在的临床应用
DOI：
10.1016/j.canlet.2021.04.010
复制
发表时间：
2021-06-02
期刊：
影响因子：
9.7
通讯作者：
Li, Zhenfei
中科院分区：
文献类型：
--
作者：
Hou, Zemin;Huang, Shengsong;Li, Zhenfei
雄激素在前列腺癌中起着重要作用。针对类固醇生成和雄激素受体 (AR) 的临床治疗成功地推迟了疾病进展。阿比特龙和恩杂鲁胺是下一代雄激素受体途径抑制剂 (ARPI)，即使在去势抵抗性前列腺癌 (CRPC) 中也强调雄激素-AR 轴的功能。然而，随着显示对 ARPI 耐药的神经内分泌前列腺癌 (NEPC) 发病率的增加，雄激素-AR 轴在进一步疾病管理中的重要性仍然难以捉摸。在此，我们回顾了与不同疾病阶段相关的类固醇生成途径，并讨论了对阿比特龙和恩杂鲁胺表现出耐药性后疾病管理的潜在目标。
Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the nextgeneration androgen receptor pathway inhibitors (ARPI), emphasize the function of the androgen-AR axis even in castration-resistant prostate cancer (CRPC). However, with the increased incidence in neuroendocrine prostate cancer (NEPC) showing resistance to ARPI, the importance of androgen-AR axis in further disease management remains elusive. Herein we review the steroidogenic pathways associated with different disease stages and discuss the potential targets for disease management after manifesting resistance to abiraterone and enzalutamide.